Preliminary Technical Works Before National Registration in Belarus: An Overview

1. Key takeaways

National registration of medical devices in Belarus is not a matter of submitting a dossier and waiting for a decision. It is a two-stage process in which a complete set of preliminary technical works must be finished first, and only once a technical conclusion has been issued does the file move into the decision stage before the Ministry of Health. The preliminary technical works are organised and implemented by a single organising body — the Republican Unitary Enterprise known as the Healthcare Appraisal and Testing Centre. Council of Ministers Resolution No. 211 frames this whole stage: it sets an overall time limit of 90 calendar days for the works, allows extension to at most 150 calendar days by agreement of the parties, and closes the list of works so that the organising body is expressly prohibited from expanding it. For a manufacturer, the practical consequence is that the project plan must be built around two clearly separated phases — a technical phase run with the expert body, and an administrative phase run with the Ministry of Health — each with its own counterpart and its own timing risks. Treating registration as one undivided procedural block is the most common planning error in this market.

2. Legal basis

3. Expert insights

Insight 1: Preliminary technical works are a front-end phase legally separated from the registration decision. Under the procedural architecture established by Resolution No. 55, the counterparty an applicant faces during this phase is the expert organisation, not the Ministry of Health. The Ministry enters the picture only after the technical conclusion has been produced, at which point it takes the registration decision and issues the certificate. This separation has real operational consequences: the two phases speak different languages, run on different clocks and expect different kinds of input. The technical phase revolves around test protocols, sample submission and equivalence arguments; the administrative phase revolves around forms, fees and formal completeness checks. A manufacturer that funnels every question through a single contact person will find that technical queries stall behind administrative paperwork and vice versa. The workable model is to maintain two parallel interfaces from day one — technical Q&A with the expert body, and administrative correspondence with the Ministry — with the authorised representative coordinating between them.

Insight 2: Resolution No. 55 governs more than its title suggests. Although the document is named for preliminary technical works before national registration, it also regulates amendments to the registration dossiers of products already registered in Belarus. In other words, first registration before market entry and post-market changes to the dossier share the same ministerial instrument as their procedural foundation. This is a deliberate design choice: it keeps the format of the dossier, the language of submissions and the interface with the expert body consistent across the life cycle of a registration. For companies, the practical reading is straightforward — when preparing change materials, the first place to look for the governing procedure is Resolution No. 55 itself, not some separate change-management rule that does not exist. Building an internal regulatory map that treats amendments as an orphan procedure is an avoidable error that surfaces late, usually when a change filing is rejected for following the wrong process.

Insight 3: The amendment history shows Resolution No. 55 is a living rule, not a relic. The resolution was issued in 2015, was amended on 2021-11-28 (excluding technical works connected with Union registration and residents of the Great Stone industrial park from its scope), and its current version is the text as amended by No. 120 of 2023-08-23. Compared with the wholesale switch of framework brought about by Resolution No. 211, Resolution No. 55 has evolved through iteration within the same document. The two instruments are therefore complementary rather than substitutive: No. 211 provides the framework, the time limits and the closed-list principle, while No. 55 remains the operational rulebook that says how each work item is actually performed. Monitoring amendments to No. 55 is thus not an academic exercise — a change to its annexes can change what work a specific product must undergo.

Insight 4: The 90-day figure is a limit for the works as a whole, not for any single step. The government press service described it as an overall time limit for a set of preliminary technical works of no more than 90 calendar days. This means document screening, testing, production site inspection and clinical evaluation are collectively bound by the limit, while the internal allocation of time among these steps is arranged by the organising body. Applicants should not assume, for example, that laboratory testing alone is entitled to consume sixty days. The distribution is a management decision inside the expert organisation, visible to the applicant only through scheduling. This argues for early engagement: agreeing indicative slots for samples, tests and any inspection at project kick-off, and tracking cumulative elapsed time against the 90-day clock, rather than discovering at day eighty that one work item has quietly absorbed the budget.

4. Practical recommendations

1. Build the schedule around a front-end phase plus a decision phase. Budget the front-end phase on a baseline of 90 calendar days with an outer cap of 150 calendar days, and estimate the decision phase separately, since the 90-day limit does not by itself cover the Ministry’s decision-making time.
2. Assign different owners to technical Q&A and administrative procedure. Do not let one contact person handle both the expert body’s technical queries and the Ministry’s administrative requests for correction; mixing the two channels is the most frequent source of missed deadlines.
3. Anchor change filings in Resolution No. 55. First registration and registration dossier amendments share the same ministerial instrument, so do not build separate procedural assumptions for changes — reuse the same document formats, language arrangements and interface channels.
4. Fix the sample submission date early. Testing cannot start until samples arrive, so sample preparation and logistics should be scheduled before, or in parallel with, document preparation — never after the dossier is drafted.

5. Verification checklist

• □ Confirmed that preliminary technical works are organised and implemented by the expert organisation, while the registration decision is taken by the Ministry of Health
• □ Front-end phase scheduled on the 90-day baseline with the 150-day outer cap
• □ Technical Q&A and administrative procedure assigned to separate contact channels
• □ Change materials prepared under the procedure of Resolution No. 55
• □ Sample submission timing incorporated into the project master plan

Regulatory information verified as of 2026-10-30.

On the Eurasian Economic Union market, GRZAN’s core capabilities concentrate on three points. First, distinguishing the applicable conditions and remaining time windows of the two pathways — Union-wide registration versus national registration in each member state: the national registration procedure for medical devices in Belarus has been switched wholesale by Council of Ministers Resolution No. 211 of 2026-04-28 (state register No. 6-1/55925, effective 2026-05-01), which compressed the total time limit for preliminary technical works to 90 calendar days, closed the list of such works and prohibited the organising body from expanding it, while the window for filing applications under the national procedure treats 2027-12-31 as the critical cut-off — pathway selection must therefore be decided in step with the time window. Second, authorised representative services: GRZAN can act as the manufacturer’s statutory representative in Belarus, undertaking registration filings, responses to technical queries, registration dossier amendments and post-market reporting obligations, and has synchronised its coordination mechanisms after Council of Ministers Resolution No. 378 of 2026-07-27 (effective 2026-07-30) transferred adverse-event functions to the state organisation for pharmaceutical supervision. Third, quality system and testing support: assistance in establishing a quality management system conforming to ISO 13485, and in organising technical documentation according to the target pathway — the national pathway follows the annex to Ministry of Health Resolution No. 55, while the Union pathway follows EEC Council Decision No. 46.

For business inquiries: info@grzanglobal.com